Loading data…
Fulcrum Therapeutics, Inc.
Qualifying buys · 30d: eligible common-stock purchases by trade date in the 30 days through October 12, 2026, using the company snapshot.
30-day filing activity: eligible purchases from filings accepted by the SEC in the last 30 days. Acceptance dates can differ from trade dates.
Value used in Signal Score: qualifying purchases across 180 days, weighted by transaction age. The calculation and exact value are in “Why this Signal Score?” below. These totals measure different windows and should not be added together.
Signal Score summarizes disclosed corporate insider buying over up to 180 days. It is separate from Congress activity and the 30-day purchase total, and does not measure company quality, investment safety or profit probability.
1 transactions · Newest trade first
Accepted in the last 30 daysNo qualifying insider buying. No qualifying insider sales.
Filing activity uses public SEC acceptance timestamps. The qualifying-buys metric above uses trade dates at the snapshot cutoff.
$803,389 of common-equity purchase value after transaction-age decay across 180 days.
1 distinct reporting-owner group(s). Joint rows count once; identity is not proof of discretion.
Signal Score describes disclosed qualifying corporate insider buying over up to 180 trade-date days. Congress trades do not contribute. It is not a measure of company quality, investment safety or profit probability. A zero means no points in the scored evidence; unavailable means imported scoring evidence is missing. Read the methodology
Open a transaction's SEC filing for the primary evidence. A code P may describe an open-market or private purchase; classification is not proof of intent.
Insider activity can have many explanations. Signal Score is not a probability of profit or a recommendation to trade.
This reflects the filings imported so far, not a complete trading history.